Self-Monitoring Systems Make Glucose Test Convenient Over Existing Measurement Threshold

The American Diabetes Association reveals that about 29.1 million people in America alone had diabetes in 2012. The figure further outlines that close to 1.25 million people in the country with type1 diabetes were both adults and kids. Industry experts at Allied Market Research explain that the disease remains the seventh maim cause of death in countries such as United States. Those gauging the size and share of the continuous glucose monitoring systems market highlight that prevalence of diabetes particularly in elders over 64 years is extremely high. 

Smartphone-enabled Systems Take a Lead in Continuous Glucose Monitoring Systems Market

Checking the glucose levels has now become convenient as checking some of your text messages on the smartphone. Alerts are now used to inform patients about their low or high sugar levels, often picked up by an existing measurement threshold. A similar device named Medtronic earned CE mark for its capabilities as Guardian Connect CGM system. 

The device can be used by individuals who need to constantly monitor their glucose level and depend on insulin injections. This device has become the first smartphone-enabled system to receive a CE mark. Annette Brüls, the president at Medtronic said “Patients can take advantage of automatic uploads to CareLink therapy management software, so there is no need for bulk data upload by patients or healthcare providers.” She further explained “Brüls noted that the CareLink system “arms healthcare providers, their patients and care partners with actionable data to help improve day-to-day diabetes management and make long-term therapy adjustments." Brüls is the president of diabetes solution as well as service at Medtronic. 

It is true that having a continuous and real–time access to a system similar to this that will alert individuals with diabetes about the vital trends as well as events is important for people with diabetes. There is an increased demand for systems that use wearable CGM systems to measure glucose level frequently and send reading to your smartphone application. A device like CareLink system performs such functions by sharing information that can be easily converted to/displayed as text messages to the care givers. The product will be inaugurated officially in 2017. 

Systems get Makeover to Perform Better in the Continuous Glucose Monitoring Systems Market

In 2016, some of the leading makers of health status and personal location remote monitoring systems for care providers are relying on cloud-based technology. In a recent incident Loon Medical, Inc., has added cloud to its CareSentinel® series. Official sources reveal that the application in CareSentinel® is a licensed product of Applivate, LLC., of the New Haven. The CT, helps patients to upload their medical records from meters via Bluetooth® technology to the CareSentinel® Cloud. The mechanism creates an extensive view for the care providers and physicians to understand the glycemic condition of a patient. The makers decided to rebrand Applivate’s ShugaTrak® as SensaCare and offer it as a platform that can be used to connect sign monitoring output to CareSentinel. By using this platform, the end users will soon get to access additional monitoring apps from CareSentinel for pulse oximetry, blood pressure, and heart rate. Caregivers can also access video for remote monitoring on their smart phones. Many manufacturers are planning to add similar features to the existing alert system and increase the remote viewing capabilities for a patient in bed or on a wheelchair, wandering, using the toilet, and for other activities. Such discoveries have opened new avenues for the continuous glucose monitoring systems market.

Get detailed information visit @: https://www.alliedmarketresearch.com/global-continuous-glucose-monitoring-system-market

FDA takes keen interest in non-adjunctive label
The number of continuous glucose monitoring systems approved by Food and Drugs Association has increased over the past few years. DexCom, Inc., a prominent market player in the CGM systems recently revealed that Clinical & Clinical Toxicology Devices Panel of U.S. FDA backed the proposal for non-adjunctive indication for the new DexCom G5 Mobile continuous glucose monitoring device. Officials indicate that when approved the G5 Mobile continuous glucose monitoring system will replace the traditional fingerstick testing for patients with diabetes. Expressing his sentiments about the recent developments, Kevin Sayer, the president at DexCom said "This recommendation is a big milestone for people with diabetes". Sayer explained "The diabetes community turned out in force to support this decision. We commend the FDA for bringing this important subject into a public forum, and thank the panel members, as well as the public speakers for their willingness to participate. We look forward to continued positive discussions with the FDA as we seek the agency's approval of our application."
The panel assessing the G5 Mobile continuous glucose monitoring system identified that the product was safe for all the proposed indications. 

CGM System Manufacturers Identify New Distributors 

Several continuous glucose monitoring system manufacturers are seen tapping new distributors for their products. In a recent incident LabStyle Innovations has identified Gemco Medical as their first authorized distributor in U.S. for their Dario Blood Glucose Monitoring device. The partnership agreement will further strengthen LabStyle’s direct– to– customer approach and its presence in the region. Commenting on the collaboration, Erez Raphael, the chief operating officer and chairman at LabStyle said in a press release “The Gemco Medical partnership will allow LabStyle to expand its reach to thousands of pharmacies and durable medical equipment dealers across the country”. Raphael explained “This expansion will also allow Dario access on commercial health plans that cover blood glucose monitoring supplies as a medical benefit.” LabStyle’s flagship product, the Dario Smart Diabetes Management Solution, is a platform for diabetes management that combines the all-in-one Dario Blood Glucose Monitoring System meter, test strips, and controls with a real-time native smartphone app that includes a variety of tools to support and engage users, doctors, and healthcare systems. Appointment of new distributors will keep the players active in the continuous glucose monitoring systems market robust. 

 

Related Post